Another study found that high CDK12 levels was associated with increased expression of immune checkpoint factors PDCD1 and CTLA-4 in prostate cancer, supporting the concept of combining CDK12 inhibitors with immune therapy [211]. The gene discussed is CDK12; the disease is prostate carcinoma.